Please ensure Javascript is enabled for purposes of website accessibility

VIVUS, Inc. and Aetna Inc's New Weight Loss Plan

By Dave Williamson – Jan 15, 2014 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Could Vivus' new weight loss partnership with Aetna be a big boost to this year's sales?

Shares of VIVUS (VVUS) were up nearly 5% yesterday, after the announced a deal with Aetna (AET) for a weight loss program for the big insurer's members. It combines both a drug and lifestyle focus for losing weight. This could potentially boost sales of VIVUS' weight loss drug Qsymia, which came to market with a lot of hype but so far has posted meager numbers.

In this video, Motley Fool health care analyst David Williamson discusses the deal, and how beneficial it could be both to VIVUS and Aetna, but he also notes that the obesity drug war that many thought would explode between Qsymia and Arena Pharmaceuticals' (ARNA) Belviq has ended up in more of a fizzle, with sales lagging expectations across the board. David then points to one competitor that may end up being far more interesting in this space with a drug that may fall right in the sweet spot between safety and efficacy, and why FDA approval for this competitor drug may be just around the corner.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

VIVUS Stock Quote
VIVUS
VVUS
Aetna Inc. Stock Quote
Aetna Inc.
AET
Arena Pharmaceuticals Stock Quote
Arena Pharmaceuticals
ARNA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.